Forfivo XL (Bupropion HCl) Patent Expiration, LOE Window & CMS Spending

Forfivo XL (Bupropion HCl) by Twi: FDA Orange Book LOE 2028-08-23, 32 AB generics, $633K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorTwi
FDA Application & PathwayN022497 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2028-08-23
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors32
2024 CMS Total Public Spend$633K
2024 Medicare Part D Spend$237K
2024 Medicaid Spend$397K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel